Amino acids and mTOR mediate distinct metabolic checkpoints in mammalian G1 cell cycle

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Saqcena, Mahesh ^a   Menon, Deepak ^a   Patel, Deven ^a   Mukhopadhyay, Suman ^a   Chow, Victor ^a   Foster, David A ^a  

^a CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; GLUTAMINE; GROWTH FACTOR; MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN; THYMIDINE; MTOR PROTEIN, HUMAN; SIGNAL PEPTIDE; TARGET OF RAPAMYCIN KINASE;

AMINO ACID TRANSPORT; ARTICLE; CANCER CELL LINE; CELL CYCLE G0 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL FUNCTION; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; M PHASE CELL CYCLE CHECKPOINT; PROTEIN EXPRESSION; PROTEIN FUNCTION; RESTRICTION POINT; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; MAMMAL; METABOLISM; NEOPLASM; PATHOLOGY; PHOSPHORYLATION; TIME; TUMOR CELL LINE;

MAMMALIA;

AMINO ACIDS; ANIMALS; CELL LINE, TUMOR; G0 PHASE; G1 PHASE CELL CYCLE CHECKPOINTS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MAMMALS; NEOPLASMS; PHOSPHORYLATION; SIROLIMUS; TIME FACTORS; TOR SERINE-THREONINE KINASES;

EID: 84904251653     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0074157     Document Type: Article

References (40)

1. Platz A, Sevigny P, Norberg T, Ring P, Lagerlöf B et al. (1996) Genes involved in cell cycle G1 checkpoint control are frequently mutated in human melanoma metastases. Br J Cancer 74: 936-941. doi:10.1038/bjc.1996.460. PubMed: 8826861.
2. Foster DA, Yellen P, Xu L, Saqcena M (2010) Regulation of G1 Cell Cycle Progression: Distinguishing the Restriction Point from a Nutrient-Sensing Cell Growth Checkpoint(s). Genes Cancer 1: 1124-1131. doi: 10.1177/1947601910392989. PubMed: 21779436.
3. Pardee AB (1974) A restriction point for control of normal animal cell proliferation. Proc Natl Acad Sci U S A 71: 1286-1290. doi:10.1073/pnas.71.4.1286. PubMed: 4524638.
4. Zetterberg A, Larsson O (1985) Kinetic analysis of regulatory events in G1 leading to proliferation or quiescence of Swiss 3T3 cells. Proc Natl Acad Sci U S A 82: 5365-5369. doi:10.1073/pnas.82.16.5365. PubMed: 3860868.
5. Schmelzle T, Hall MN (2000) TOR, a central controller of cell growth. Cell 103: 253-262. doi:10.1016/S0092-8674(00)00117-3. PubMed: 11057898.
6. Fingar DC, Blenis J (2004) Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 23: 3151-3171. doi:10.1038/sj.onc. 1207542. PubMed: 15094765.
7. Hartwell LH, Culotti J, Pringle JR, Reid BJ (1974) Genetic control of the cell division cycle in yeast. Science 183: 46-51. doi:10.1126/science. 183.4120.46. PubMed: 4587263.
8. Jorgensen P, Rupes I, Sharom JR, Schneper L, Broach JR et al. (2004) A dynamic transcriptional network communicates growth potential to ribosome synthesis and critical cell size. Genes Dev 18: 2491-2505. doi:10.1101/gad.1228804. PubMed: 15466158.
9. Cardenas ME, Cutler NS, Lorenz MC, Di Como CJ, Heitman J (1999) The TOR signaling cascade regulates gene expression in response to nutrients. Genes Dev 13: 3271-3279. doi:10.1101/gad.13.24.3271. PubMed: 10617575.
10. Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP et al. (1998) Extension of life-span by introduction of telomerase into normal human cells. Science 279: 349-352. doi:10.1126/science.279.5349.349. PubMed: 9454332.
11. Yellen P, Saqcena M, Salloum D, Feng J, Preda A et al. (2011) Highdose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1. Cell Cycle 10: 3948-3956. doi:10.4161/cc.10.22.18124. PubMed: 22071574.
12. Iyer VR, Eisen MB, Ross DT, Schuler G, Moore T et al. (1999) The transcriptional program in the response of human fibroblasts to serum. Science 283: 83-87. doi:10.1126/science.283.5398.83. PubMed: 9872747.
13. Chen KH, Harris DL, Joyce NC (1999) TGF-beta2 in aqueous humor suppresses S-phase entry in cultured corneal endothelial cells. Invest Ophthalmol Vis Sci 40: 2513-2519. PubMed: 10509644.
14. Rialland M, Sola F, Santocanale C (2002) Essential role of human CDT1 in DNA replication and chromatin licensing. J Cell Sci 115: 1435-1440. PubMed: 11896191.
15. Muise-Helmericks RC, Grimes HL, Bellacosa A, Malstrom SE, Tsichlis PN et al. (1998) Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase/Akt-dependent pathway. J Biol Chem 273: 29864-29872. doi:10.1074/jbc.273.45.29864. PubMed: 9792703.
16. Franke TF, Yang SI, Chan TO, Datta K, Kazlauskas A et al. (1995) The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell 81: 727-736. doi: 10.1016/0092-8674(95)90534-0. PubMed: 7774014.
17. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098-1101. doi:10.1126/science.1106148. PubMed: 15718470.
18. Noda T, Ohsumi Y (1998) Tor, a phosphatidylinositol kinase homologue, controls autophagy in yeast. J Biol Chem 273: 3963-3966. doi:10.1074/jbc.273.7.3963. PubMed: 9461583.
19. Baldin V, Lukas J, Marcote MJ, Pagano M, Draetta G (1993) Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev 7: 812-821. doi:10.1101/gad.7.5.812. PubMed: 8491378.
20. Sherr CJ, Roberts JM (1999) CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13: 1501-1512. doi: 10.1101/gad.13.12.1501. PubMed: 10385618.
21. LaBaer J, Garrett MD, Stevenson LF, Slingerland JM, Sandhu C et al. (1997) New functional activities for the p21 family of CDK inhibitors. Genes Dev 11: 847-862. doi:10.1101/gad.11.7.847. PubMed: 9106657.
22. Yen A, Pardee AB (1978) Arrested states produced by isoleucine deprivation and their relationship to the low serum produced arrested state in Swiss 3T3 cells. Exp Cell Res 114: 389-395. doi: 10.1016/0014-4827(78)90497-4. PubMed: 679990.
23. Polak P, Hall MN (2009) mTOR and the control of whole body metabolism. Curr Opin Cell Biol 21: 209-218. doi:10.1016/j.ceb. 2009.01.024. PubMed: 19261457.
24. Xu L, Salloum D, Medlin PS, Saqcena M, Yellen P et al. (2011) Phospholipase D mediates nutrient input to mammalian target of rapamycin complex 1 (mTORC1). J Biol Chem 286: 25477-25486. doi: 10.1074/jbc.M111.249631. PubMed: 21622984.
25. Inoki K, Kim J, Guan KL (2012) AMPK and mTOR in cellular energy homeostasis and drug targets. Annu Rev Pharmacol Toxicol 52: 381-400. doi:10.1146/annurev-pharmtox-010611-134537. PubMed: 22017684.
26. Foster DA (2007) Regulation of mTOR by phosphatidic acid? Cancer Res 67: 1-4. doi:10.1158/0008-5472.CAN-06-3016. PubMed: 17210675.
27. Athenstaedt K, Daum G (1999) Phosphatidic acid, a key intermediate in lipid metabolism. Eur J Biochem, 266: 1-16/FEBS 266: 1-16 PubMed: 10542045.
28. Mérida I, Avila-Flores A, Merino E (2008) Diacylglycerol kinases: at the hub of cell signalling. Biochem J 409: 1-18. doi:10.1042/BJ20071674. PubMed: 18062770.
29. Foster DA (2013) Phosphatidic acid and lipid-sensing by mTOR. Trends Endocrinol Metab 24: 272-278. doi:10.1016/j.tem.2013.02.003. PubMed: 23507202.
30. Cross FR, Buchler NE, Skotheim JM (2011) Evolution of networks and sequences in eukaryotic cell cycle control. Philos Trans R Soc Lond B Biol Sci 366: 3532-3544. doi:10.1098/rstb.2011.0078. PubMed: 22084380.
31. Stiles CD, Capone GT, Scher CD, Antoniades HN, Van Wyk JJ et al. (1979) Dual control of cell growth by somatomedins and platelet-derived growth factor. Proc Natl Acad Sci U S A 76: 1279-1283. doi: 10.1073/pnas.76.3.1279. PubMed: 312500.
32. Loyer P, Cariou S, Glaise D, Bilodeau M, Baffet G et al. (1996) Growth factor dependence of progression through G1 and S phases of adult rat hepatocytes in vitro. Evid A Mitogen Restriction Point Mid-Late G1. J Biol Chem 271: 11484-11492
33. Coutant A, Rescan C, Gilot D, Loyer P, Guguen-Guillouzo C et al. (2002) PI3K-FRAP/mTOR pathway is critical for hepatocyte proliferation whereas MEK/ERK supports both proliferation and survival. Hepatology 36: 1079-1088. doi:10.1053/jhep.2002.36160. PubMed: 12395317.
34. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100: 57-70. doi:10.1016/S0092-8674(00)81683-9. PubMed: 10647931.
35. Ward PS, Thompson CB (2012) Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 21: 297-308. doi: 10.1016/j.ccr.2012.02.014. PubMed: 22439925.
36. Blagosklonny MV (2011) Molecular damage in cancer: an argument for mTOR-driven aging. Aging 3: 1130-1141. PubMed: 22246147.
37. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674. doi:10.1016/j.cell.2011.02.013. PubMed: 21376230.
38. Yeung SJ, Pan J, Lee MH (2008) Roles of p53, MYC and HIF-1 in regulating glycolysis-the seventh hallmark of cancer. Cell Mol Life Sci 65: 3981-3999. doi:10.1007/s00018-008-8224-x. PubMed: 18766298.
39. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB (2008) The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 7: 11-20. doi:10.1016/j.cmet.2007.10.002. PubMed: 18177721.
40. Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324: 1029-1033. doi:10.1126/science.1160809. PubMed: 19460998.